This review describes trends in the burden of cardiovascular diseases (CVDs) and risk factors in India compared with the United States; provides potential explanations for these differences; and describes strategies to improve cardiovascular health behaviors, systems, and policies in India. The prevalence of CVD in India has risen over the past 2 decades due to population growth, aging, and a stable age-adjusted CVD mortality rate. Over the same time period, the United States has experienced an overall decline in age-adjusted CVD mortality, although the trend has begun to plateau. These improvements in CVD mortality in the United States are largely due to favorable population-level risk factor trends, specifically with regard to tobacco use, cholesterol, and blood pressure, although improvements in secondary prevention and acute care have also contributed. To realize similar gains in reducing premature death and disability from CVD, India needs to implement population-level policies while strengthening and integrating its local, regional, and national health systems.
I n response to the United Nations Declaration on Noncommunicable Diseases (NCDs) in 2011, the World Health Organization (WHO) set the goal of reducing the risk of premature mortality (30 to 69 years of age) from NCDs, including cardiovascular diseases (CVDs), by 25% by 2025 (1) . Beyond 2025, the United Nations has also created Sustainable Development Goals, including the goal of promoting good health and well-being, with an even more ambi-tious subgoal of reducing the burden of premature mortality from NCDs, including CVD, by one third by 2030 (2) . Thus, cardiovascular (CV) health promotion and disease prevention and control are firmly on the global agenda.
Overall, the absolute burden of CVD has increased globally and has shifted heavily toward low-and middle-income countries (LMICs) such as India, largely because of population growth and aging (3) .
As an LMIC, India has not experienced a decline in age-adjusted CVD event rates and continues to undergo an epidemiological transition from predominantly infectious diseases to NCDs. This transition has occurred over a compressed time frame, leading to a dual burden of disease, albeit with substantial subnational variation.
Addressing this significant burden of CVD in such a large, complex, and rapidly developing country requires an understanding of the complex dynamics of CVD risk factors and their interactions.
Therefore, based on the formidable disease burden, global health goals, and regional contexts, the objectives of the present paper were to: 1) describe trends in the burden of CVD and its risk factors in India (4) . Ischemic heart disease and stroke were estimated to account for approximately 15% to 20% and 6% to 9% of all deaths in these regions (5) . Table 1 displays trends in age-standardized CVD prevalence per 100,000 and the estimated number of prevalent cases of CVD in India and the United States in 1990 and 2016. The estimated age-standardized prevalence of CVD in India in 2016 was 5,681 per 100,000 (4). This rate was lower than the agestandardized prevalence in the United States (7, 405) . However, because of India's large population, the absolute estimated prevalence of CVD in India (54.6 million) is >60% larger than in the United States and 2016, although this number seems to be almost entirely due to population aging (3) . However, there is substantial state-level variability in the burden of CVD in India, including a 9-fold variation in the burden of ischemic heart disease disability-adjusted life years (DALYs) per 100,000 persons between the states with the highest (Punjab) and lowest (Mizoram) burdens. Likewise, there was a 6-fold variation in the rate of stroke DALYs between the highest-burden (West Bengal) and lowest-burden (Mizoram) states ( Figure 1) (6) . Reasons for state-level differences in mortality and morbidity are myriad, and are likely driven by differences in risk factor burden, treatment, control, management of acute manifestations of CVD, and, perhaps, baseline event rates. Analysis of the CVD burden attributable to modifiable risk factors suggests that common risks, such as smoking, may play a variable role among Indian states (4) .
In contrast, the long-term U.S. trend shows a decline in CVD mortality, from 300 deaths per 100,000 in 1990 to 176 deaths per 100,000 (age-standardized) in 2016. Over the past 5 years, CVD age-standardized death rates are no longer declining in the United States, a trend not entirely accounted for by population aging (5) . (8, 9) . Several notable, prospective, longitudinal studies in India are summarized in Table 3 . In 1960, the urban population represented 70% and 18% of the U.S. and Indian populations, respectively, and, in 2016, the corresponding proportions were 82% and 33%, (17) . The rapidity, trajectory, and unevenness of urbanization and its relationship with increased prevalence of CVD risk factors partly explain the increasing CVD mortality in India (18) .
Lower socioeconomic position is now inversely associated with most CV risk factors and CVD in both regions (19) . Despite broad economic gains associated with globalization and urbanization, socioeconomic inequalities persist, especially in India, and continue to contribute to the growing CVD burden. The concomitant, large, and persistent burden of communicable and poverty-related diseases further stresses the Indian health system and its response to acute and chronic CVD. ACCESS TO HIGH-QUALITY CARE. The burden of CV risk factors is lowest in low-income countries, but rates of major CVD events and CVD-related mortality are higher in low-income countries compared with high-income countries (21) . This discordance between the baseline level of risk and subsequent event and mortality rates may be driven by differences in the stage of clinical presentation, quality of CVD acute and chronic CV care across countries, or a combination thereof (21) . For example, in India, 80% of individuals with ischemic heart disease or stroke take no secondary prevention medicines (22) . Although community-based rates of secondary preventive pharmacotherapy are higher in the United States,
representative data from the National Health and Nutrition Examination Survey also show major gaps in adherence (23) . In the United States, regional variations in CVD are partly due to variations in access to high-quality CVD services (24) . Asian subjects (27) . Even the threshold of risk associated with absolute risk factor levels, such as the threshold between BMI and incident diabetes mellitus, may be lower in South Asian subjects compared with other ethnic groups. The underlying basis for these differences may be genetic, such as particular loci associated with hypertension and CVD risk (28) .
Epigenetic influences may also contribute, even in the context of genetic results that show modest ef- Other studies have also reported associations between infectious diseases and CVD (32) . For example, malaria is associated with gestational hypertension and pre-eclampsia (33) , which are risk factors for low birth weight. Because children with low birth weight are at an increased risk of hypertension and ischemic heart disease later in life (30, 34) , the interaction between infections, birth weight, hypertension, and incident CVD may warrant further study (32) .
STRATEGIES TO IMPROVE CV HEALTH

PROMOTION, DISEASE PREVENTION, AND CONTROL SYSTEMS AND POLICIES IN INDIA
Improvements in the age-adjusted mortality rate from CVD over the past few decades in high-income countries are due largely to favorable populationlevel risk factor trends, specifically with regard to smoking, cholesterol, and systolic blood pressure.
Improvements in secondary prevention and acute care have also contributed (18). India will similarly, but more quickly, need to scale up primordial, primary, secondary, and tertiary prevention initiatives to reduce CVD burden, and it may need to use more creative strategies to contend with the limited resources and larger population in the Indian context.
In the following sections, we review prevention and treatment strategies that have been effective in the Prabhakaran et al. analysis showed that a benefit-based tailored treatment strategy emphasizing lowering of CVD risk was more effective and cost-effective in reducing CVD deaths in India than a treat-to-target strategy (i.e., lowering blood pressure to a target or a hybrid strategy currently recommended by the WHO). The benefit-based tailored treatment strategy could help achieve more than one-third of the WHO's CVD mortality target (46) . SECONDARY PREVENTION. The use of therapies to prevent recurrence of coronary heart disease and stroke in India is suboptimal (22) . Strategies to improve adherence in the secondary prevention population are generally similar to those used in primary prevention populations; for example, use of fixed-dose combination therapy, task-sharing interventions, and integration of multicomponent interventions. The major completed and ongoing studies from India are listed in Table 3 .
Cardiovascular Diseases in India
In addition to these strategies, cardiac rehabilita- across a broad spectrum of treatment access and adherence levels (52) . Future quality improvement initiatives and programs will need to evaluate the following: 1) the spread and sustainability of these promising activ- Although the United States is stronger in many of these areas, underserved populations and minorities also suffer from the lack of universal health care and financial protection.
CONCLUSIONS
The United States has experienced substantial de- 
